CHAPTER 55 — REFERENCES
74. Janeway KA, Albritton KH, Van Den Abbeele AD, et al. Sunitinib treat-
69. Blanke CD, Rankin C, Demetri GD et al. Phase III randomized, intergroup
64. Wang D, Zhang Q, Blanke CD, et al. Phase II trial of neoadjuvant/adjuvant
57. Joensuu H, Eriksson M, Sundby Hall K, et al. One vs three years of adju-
59. Casali PG, Fumagalli E, Gronchi A. Adjuvant therapy of gastrointestinal stro-
90. Demetri GD, Wang Y, Wehrle E, et al. Imatinib plasma levels are correlated
99. Demetri GD, Jeffers M, Reichardt P, et al. Mutation analysis of plas-
104. Choi H, Charnsangavej C, Faria SC, et al. Correlation of computed tomog-
102. Van den Abbeele AD. The lessons of GIST—PET and PET/CT: a new para-
103. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation crite-
104. Choi H, Charnsangavej C, Faria SC, et al. Correlation of computed tomog-
105. Joensuu H, Eriksson M, Sundby Hall K, et al. One vs three years of adju-
106. Rutkowski P, Corless CL, Hohenberger P, et al. Neoadjuvant imatinib in lo-
111. Joensuu H, Eriksson M, Sundby Hall K, et al. One vs three years of adju-
112. Rutkowski P, Corless CL, Hohenberger P, et al. Neoadjuvant imatinib in lo-